Novartis India: agrochemical spin off will improve numbers - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Outlook Arena
  • May 24, 2000 - Novartis India: agrochemical spin off will improve numbers

Novartis India: agrochemical spin off will improve numbers

May 24, 2000

Novartis India is a 50.99% subsidiary of the Novartis Switzerland, the world leader in pharmaceuticals and agrochemicals. The company has 5 brands that contribute almost 45% of its formulation sales

Major formulations % Pharma
Sales (approx)
Voveran (NSAIDs) 17.0%
Otrivin (Nasal decongestation) 5.0%
Tegrital (anti–epileptic) 12.0%
Rimactizid (anti–TB) 6.0%
Macalvit (calcium Supplement) 5.0%

The international parent has proposed the separation of its agrochemical arm and its merger with the agrochemical arm of Astra Zeneca to form a new company Syngenta. In India too the same process is underway. This is similar to the move that Wockhardt India has made in India i.e. separating its agrochemical arm and becoming a focused pharma company.

Healthcare (this includes the vision care division and the animal health division) contributes approx. 50% of the Novartis total turnover. The overall operating margins of the company are around 17% and these can be expected to increase to around 22% post the hive off of the agrochemical division. Also, the company would be able to reduce its working capital requirements since the inventory days and debtors days can almost be halved from the present levels of 70 days and 55 days respectively.

New Products Purpose
Femara for treatment of advanced breast cancer
Exelon for management of Alzheimer's disease
Epitril for treatment of epilepsy and panic disorders
PZA–1000 for treatment of TB
3FD for treatment of TB

Thus the spin off would leave Novartis India with a stable non–seasonal business (since for agro–chemical business, the first half is normally much better than the second half). Besides, the company has launched five new products over the last two years (see table) all of which are out of the purview of the Drug Price Control Order. This can be expected to improve the margins further.

The improvement in profits, the removal of a seasonal business, the introduction of new products coupled with the almost zero debt status of the company should spell good times for the company. The stock quotes at Rs 618 (52 week range: 1436/618) an earning multiple of 26 times its FY99 earnings.

Equitymaster requests your view! Post a comment on "Novartis India: agrochemical spin off will improve numbers". Click here!

  

More Views on News

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

This One Smallcap Stock is a Must Have in Your Portfolio (Profit Hunter)

Nov 11, 2020

Investing in this smallcap could open doors of huge, long-lasting wealth.

This Diwali Consider Richa's #1 Stock Pick for 2021 (Profit Hunter)

Nov 13, 2020

Why I admire the approach that Richa uses to zero in on stocks with huge upside potential.

Should You Buy Gold Now? (Fast Profits Daily)

Nov 11, 2020

Pfizer has announced a vaccine for covid-19. In response, gold prices have fallen. Should you buy? Find out in this video..

Don't Let Brokerages Fool You into Buying HUL & Nestle. The Real Money is in These Stocks Right Now... Views On News (Views On News)

Nov 12, 2020

Rahul Shah discusses why he preferred a little known stock over Nestle Ltd and how he was proven right.

US Elections: Won a Battle, Now the War (The Honest Truth)

Nov 13, 2020

Ajit Dayal on the urgent need to fix the disparity between the rich and the poor in the US.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Nov 24, 2020 03:36 PM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - VENUS REMEDIES COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS